Creatine Gummies: Formulation and Manufacturing Feasibility

A 2026 randomized trial assigned female collegiate and professional beach-volleyball athletes to either 5 g/day creatine monohydrate gummies or a non-supplemented control for 10 weeks. The study demonstrates that a 5 g/day creatine-monohydrate dose was delivered using a gummy product in that research setting.

It does not disclose or establish a universal gummy count, unit weight, formulation, active fraction, commercial manufacturing limit, shelf life or sensory standard. It is evidence of delivery in one study—not a transferable commercial formula.

Use 5 g/day here as an arithmetic example, not as a requirement for every creatine product.

This table divides a stated dose. It does not prove that any row is physically, sensorially or commercially feasible.

HYPOTHETICAL 4 g FINISHED-GUMMY EXAMPLE — NOT A FEASIBILITY CLAIM

At two gummies per day:

2.5 g creatine per gummy ÷ 4 g finished gummy = 62.5% nominal creatine fraction

At five gummies per day:

1 g creatine per gummy ÷ 4 g finished gummy = 25% nominal creatine fraction

The remaining mass still has to support the gel, sweetener or bulk system, water system, acids or buffers, flavour, colour where used, processing and finishing. Neither result establishes manufacturability. Use the full payload and serving architecture framework before treating the arithmetic as a product direction.

Fewer gummies reduce daily unit count but increase the active burden per unit and leave less formulation space. More gummies reduce the per-unit burden but increase consumer effort, monthly pack count, packaging and potentially cost.

At five gummies per day:

5 × 30 days = 150 gummies per month

That may be technically easier per unit while creating a much larger commercial and consumer commitment. The correct serving is the smallest architecture that remains technically, sensorially and commercially credible—not automatically one gummy or five.

Do not casually treat “creatine,” “creatine monohydrate” and raw-material input mass as interchangeable.

Formula calculations should use the actual ingredient specification and assay, the intended labelled basis, and the applicable test method. No potency conversion or overage should be assumed without the real material and validated product specification.

A high creatine load can create suspended-solids, chalkiness, grittiness, mouthfeel, chew, flavour, aftertaste and unit-size challenges. The direction and severity depend on the actual material and formula.

The maximum physically incorporable load may be higher than the maximum sensorially acceptable load. Sensory work belongs inside the active-containing gummy formulation, not in a blank base.

Published work found creatine degradation changed with water activity and temperature in defined glycerol-buffer systems, while creatine in crystalline form was highly stable before reaching the studied deliquescence condition. Separate aqueous-solution research on an effervescent creatine formulation observed degradation and crystallisation under that solution's conditions.

These studies explain why water, temperature, pH and physical state matter. Their rates and conditions must not be transferred directly to gummies.

The correct conclusion is: creatine stability in a gummy must be demonstrated in the actual formulation and package through a product-specific stability plan.

Gummies commonly use acidic systems for sensory and formulation purposes. Creatine stability research in aqueous systems makes pH, water availability, temperature and time relevant questions, but it does not provide a universal “safe pH” for gummies.

The acid system has to satisfy sensory and matrix requirements while the actual creatine assay and relevant degradation behaviour are followed through the intended process and shelf life.

A useful program should define or measure:

• target daily dose and labelled basis;
• creatine form, specification and assay;
• gummies per day, unit weight and nominal material fraction;
• hydrocolloid and solids system;
• dispersion, sedimentation and unit consistency where relevant;
• grittiness, chew, flavour and aftertaste;
• pH, moisture and water activity;
• initial and retained creatine assay;
• relevant degradation products where justified by the analytical plan;
• package and pack count;
• cost per day and serving burden.

The commercial manufacturing process must then show that the selected architecture can be produced and tested reproducibly.

Passing one lens does not imply the others have passed.

If the required dose forces an excessive unit count, very large gummies, unacceptable texture, difficult stability, unattractive packaging or poor economics, another format may be more appropriate.

Powders, stick packs or another higher-payload architecture may deserve evaluation, depending on the product. CoManufacturing's job is to help determine whether the product should be a gummy—not to sell the format at all costs.

Evidence guide: Published evidence — supported by the linked literature. · CoManufacturing experience — practical development or commercial planning context, not a universal specification. · Manufacturer-specific — confirm against the selected process and supplier. · Project-specific / requires validation — prove with the actual formula, process, pack and market.

• Pereira et al., “Effects of Creatine Monohydrate Gummies on Performance and Body Composition in Female Beach Volleyball Athletes,” 2026. Full text
• Uzzan et al., “Effect of water activity and temperature on the stability of creatine during storage,” Drug Development and Industrial Pharmacy 35 (2009): 1003–1008. PubMed · doi:10.1080/03639040902755197
• Ganguly, Jayappa and Dash, “Evaluation of the stability of creatine in solution prepared from effervescent creatine formulations,” AAPS PharmSciTech 4 (2003): E25. PubMed · doi:10.1208/pt040225

The human trial establishes use of a 5 g/day gummy dose in its study population. The stability papers studied defined model or aqueous systems; neither supplies a commercial creatine-gummy formula, stability rate or shelf-life specification.